We are delighted to share that MedTech Strategist has featured RebrAIn in their latest issue.
The article explores how our supervised AI-driven platform, OptimMRI, simplifies precision targeting for Deep Brain Stimulation (DBS) in Parkinson’s Disease. By enhancing accuracy and reducing costs, RebrAIn aims to make DBS procedures faster, safer, and more accessible. Our innovative approach is set to transform neurosurgical practices, offering improved outcomes for patients.
Read more about our advancements and future plans in the full PDF version of the article.
